Efficacy of Mesenchymal Stem Cells in the Treatment of Peritoneal Fibrosis in Animal Models: a Systematic Review and Meta-analysis

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2024 Dec 16

PMID 39681477

Authors

Lingqian Zheng

Wenmin Chen

Kaijin Yao

Yina Xie

Chunling Liao

Yongda Lin

Tianbiao Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Peritoneal fibrosis is a serious complication of long-term peritoneal dialysis, often resulting in functional deterioration and withdrawal from therapy. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory and antifibrotic effects in various models. This meta-analysis evaluated the efficacy of MSCs therapy in animal models of peritoneal fibrosis.

Methods: A comprehensive search of PubMed, the Cochrane Library, Web of Science, and EMBASE was conducted for studies published up to April 27, 2024. Two independent reviewers (LQZ and WMC) screened studies for inclusion, extracted data, and analyzed outcomes using RevMan 5.3 and STATA 17.0.

Result: Fifteen studies met the inclusion criteria. MSC therapy significantly reduced inflammatory cytokines, including IL-6, TGF-β (SMD = -1.79, 95% CI: -2.32, -1.25, < 0.00001), and TNF-α (SMD = -1.57, 95% CI: -2.71, -0.44, = 0.006) levels. Additionally, MSCs reduced submesothelial thickness (MD = -63.14, 95% CI: -78.52, -47.76, < 0.00001), Collagen I and Collagen III levels. MSCs treatment also improved ultrafiltration capacity (MD = 1.21, 95% CI: 0.64, 1.77, < 0.0001), D/D0 of glucose and E-cadherin levels. However, no significant differences were observed in VEGF, D/P of Na, D/P of BUN, D/P of protein, or glucose mass transfer between the MSCs treatment group and the control group.

Conclusion: MSC therapy significantly improves peritoneal function and attenuates fibrotic and inflammatory responses in animal models. These findings highlight the potential of MSCs as a promising therapeutic strategy for managing peritoneal fibrosis in clinical settings.

References

Margetts P, Bonniaud P . Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int. 2004; 23(6):530-41. View

Costalonga E, Fanelli C, Garnica M, Noronha I . Adipose-Derived Mesenchymal Stem Cells Modulate Fibrosis and Inflammation in the Peritoneal Fibrosis Model Developed in Uremic Rats. Stem Cells Int. 2020; 2020:3768718. PMC: 7256710. DOI: 10.1155/2020/3768718. View

Li D, Lu Z, Li X, Xu Z, Jiang J, Zheng Z . Human umbilical cord mesenchymal stem cells facilitate the up-regulation of miR-153-3p, whereby attenuating MGO-induced peritoneal fibrosis in rats. J Cell Mol Med. 2018; 22(7):3452-3463. PMC: 6010808. DOI: 10.1111/jcmm.13622. View

Zhao J, Zhao L, Zhan Q, Liu M, Zhang T, Chu W . BMSC-derived Exosomes Ameliorate Peritoneal Dialysis-associated Peritoneal Fibrosis via the Mir-27a-3p/TP53 Pathway. Curr Med Sci. 2024; 44(2):333-345. DOI: 10.1007/s11596-024-2853-7. View

Jiao T, Huang Y, Sun H, Yang L . Exosomal lnc-CDHR derived from human umbilical cord mesenchymal stem cells attenuates peritoneal epithelial-mesenchymal transition through AKT/FOXO pathway. Aging (Albany NY). 2023; 15(14):6921-6932. PMC: 10415546. DOI: 10.18632/aging.204883. View

Mortier S, Faict D, Schalkwijk C, Lameire N, De Vriese A . Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int. 2004; 66(3):1257-65. DOI: 10.1111/j.1523-1755.2004.00879.x. View

Zhang K, Zhang H, Zhou X, Tang W, Xiao L, Liu Y . miRNA589 regulates epithelial-mesenchymal transition in human peritoneal mesothelial cells. J Biomed Biotechnol. 2012; 2012:673096. PMC: 3479401. DOI: 10.1155/2012/673096. View

Wang H, Hung S, Peng S, Huang C, Wei H, Guo Y . Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells. 2004; 22(7):1330-7. DOI: 10.1634/stemcells.2004-0013. View

Kim H, Mizuno M, Furuhashi K, Katsuno T, Ozaki T, Yasuda K . Rat adipose tissue-derived stem cells attenuate peritoneal injuries in rat zymosan-induced peritonitis accompanied by complement activation. Cytotherapy. 2013; 16(3):357-68. DOI: 10.1016/j.jcyt.2013.10.011. View

10.

Huang Y, Ma J, Fan Y, Yang L . Mechanisms of human umbilical cord mesenchymal stem cells-derived exosomal lncRNA GAS5 in alleviating EMT of HPMCs via Wnt/β-catenin signaling pathway. Aging (Albany NY). 2023; 15(10):4144-4158. PMC: 10258012. DOI: 10.18632/aging.204719. View

11.

Bastug F, Gunduz Z, Tulpar S, Torun Y, Akgun H, Dorterler E . Mesenchymal stem cell transplantation may provide a new therapy for ultrafiltration failure in chronic peritoneal dialysis. Nephrol Dial Transplant. 2013; 28(10):2493-501. DOI: 10.1093/ndt/gft089. View

12.

Kang I, Lee B, Choi S, Lee J, Kim J, Kim B . Donor-dependent variation of human umbilical cord blood mesenchymal stem cells in response to hypoxic preconditioning and amelioration of limb ischemia. Exp Mol Med. 2018; 50(4):1-15. PMC: 5938050. DOI: 10.1038/s12276-017-0014-9. View

13.

Masola V, Bonomini M, Borrelli S, Di Liberato L, Vecchi L, Onisto M . Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis. Int J Mol Sci. 2022; 23(9). PMC: 9102299. DOI: 10.3390/ijms23094831. View

14.

Zheng L, Chen W, Yao K, Xie Y, Liao C, Zhou T . Clinical and preclinical studies of mesenchymal stem cells to alleviate peritoneal fibrosis. Stem Cell Res Ther. 2024; 15(1):237. PMC: 11290310. DOI: 10.1186/s13287-024-03849-3. View

15.

Ye H, Zhou Q, Fan L, Guo Q, Mao H, Huang F . The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol. 2017; 18(1):186. PMC: 5460447. DOI: 10.1186/s12882-017-0588-4. View

16.

Tulpar S, Poyrazoglu M, Ozbilge H, Bastug F, Gunduz Z, Torun Y . Modulation of inflammation by mesenchymal stem cell transplantation in peritoneal dialysis in rats. Ren Fail. 2012; 34(10):1317-23. DOI: 10.3109/0886022X.2012.725290. View

17.

Schilte M, Celie J, Ter Wee P, Beelen R, van den Born J . Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. Perit Dial Int. 2009; 29(6):605-17. View

18.

Zhou L, Zong M, Guan Q, da Roza G, Wang H, Qi H . Protection of the Peritoneal Membrane by Peritoneal Dialysis Effluent-Derived Mesenchymal Stromal Cells in a Rat Model of Chronic Peritoneal Dialysis. Stem Cells Int. 2019; 2019:8793640. PMC: 6766137. DOI: 10.1155/2019/8793640. View

19.

Trivedi A, Lin M, Miyazawa B, Nair A, Vivona L, Fang X . Inter- and Intra-donor variability in bone marrow-derived mesenchymal stromal cells: implications for clinical applications. Cytotherapy. 2024; 26(9):1062-1075. DOI: 10.1016/j.jcyt.2024.03.486. View

20.

Zhang C, Zhou L, Wang Z, Gao W, Chen W, Zhang H . Eradication of specific donor-dependent variations of mesenchymal stem cells in immunomodulation to enhance therapeutic values. Cell Death Dis. 2021; 12(4):357. PMC: 8024246. DOI: 10.1038/s41419-021-03644-5. View